Do we need hepatitis A booster vaccinations?

Journal of Travel Medicine

Volumn 11, Issue 3, 2004, Pages 179-181

  Van Damme, Pierre A ^a   Van Herck, Koen ^a   Banatvala, Jangu E ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ANTIBODY TITER; CELLULAR IMMUNITY; DRUG DOSE REGIMEN; DRUG INDICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS A; HEPATITIS A VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFECTION PREVENTION; PRACTICE GUIDELINE; REVIEW; SEROCONVERSION; TREATMENT INDICATION; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 3142515967     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.2310/7060.2004.18479     Document Type: Review

References (18)

1. André F, Van Damme P, Safary A, et al. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines 2002; 1:9-23.
2. Van Herck K, Beutels P, Van Damme P, et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 2000; 60:1-7.
3. Bovier PA, Bock J, Loutan L, et al. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 2002; 68(4):489-493.
4. Wiens BL, Bohidar NR, Pigeon JG, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 1996; 49:235-241.
5. World Health Organization. WHO position paper on hepatitis A vaccines. Wkly Epidemiol Rec 2000; 75:38-44.
6. Kane M, Banatvala J, Van Damme P, et al. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355:561-565.
7. Van Damme P, Banatvala J, Fay O, et al. Hepatitis A booster vaccination: is there a need? International Consensus Group on HAV Immunity. Lancet 2003; 362:1065-1071.
8. Van Herck K, Van Damme P, Lievens M, et al. Hepatitis A vaccine: indirect evidence of immune memory 12 years after primary course. J Med Virol 2004; 72:194-196.
9. Williams J, Bruden D, McMahon B, et al. Hepatitis A vaccine: immunogenicity following administration of a delayed inmmnization schedule in infants, children and adults. Vaccine 2003; 23:3208-3211.
10. Troisi CL, Hollinger FB, Krause DS, et al. Immunization of seronegative infants with hepatitis A vaccine (HAVRIX;SKB): a comparative study of two dosing schedules. Vaccine 1997; 15:1613-1617.
11. Dagan R, Amir J, Mijalovsky A, et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 2000; 19:1045-1052.
12. Piazza M, Safary A, Vegnente A, et al. Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme. Vaccine 1999; 17:585-588.
13. Fiore AE, Shapiro C, Sabin KM, et al. Persistence of protective antibody concentrations and response to a booster among children given hepatitis A vaccine during infancy: effect of maternal antibody. In: Proceedings of the 39th Annual Meeting of the Infectious Diseases Society of America (IDSA), San Francisco. San Francisco: Infectious Diseases Society of America, 2001:378.
14. Khuroo MS. Viral hepatitis in international travellers: risks and prevention. Int J Antimicrob Agents 2003; 21:143-152.
15. Zuckerman J, Steffen R. Risks of hepatitis B in travelers as compared to immunization status. J Travel Med 2000; 7:170-174.
16. Steffen R, Kane M, Shapiro C. Epidemiology and prevention of hepatitis A in travellers. JAMA 1994; 272:885-889.
17. Van Damme P, Leroux-Roels G, Law B, et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 2001; 65:6-13.
18. Tilzey AJ. Hepatitis B vaccine boosting: the debate continues. Lancet 1995; 345:1000-1001.